Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2026
Principal Office: Sunnyvale, California
Business Focus: The company is developing the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
Key Financial Metrics
This filing is a regulatory disclosure regarding a regulatory milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the receipt of minutes from a Q-Sub Meeting with the FDA Center for Biologics Evaluation and Research (CBER). The minutes confirm that the ongoing CardiAMP Heart Failure II Trial may be used to support Premarket Approval (PMA) for market clearance.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA meeting minutes provide a pathway for the ongoing clinical trial to support PMA, a critical step toward market clearance.
- Management Commentary: The company issued a press release (Exhibit 99.1) detailing the FDA interaction.
- Risks and Contingencies: The filing does not explicitly list new risks, though the reliance on the CardiAMP Heart Failure II Trial for PMA implies that trial outcomes remain a critical contingency for commercialization.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the FDA meeting.
- Confirm the current status and enrollment numbers of the CardiAMP Heart Failure II Trial.
- Review subsequent filings for any updates on the timeline for submitting the Premarket Approval (PMA) application.
- Check the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial data.